Terremoto Biosciences will get $75M to Develop Covalent Medicines
San Francisco-based Terremoto Biosciences launched with $75 million in Sequence A financing to develop extremely focused, small-molecule medicines. The financing was co-led by OrbiMed and Third Rock Ventures. With the funds, Terremoto plans to advance its lysine-targeted covalency platform and create therapies for beforehand untreatable ailments. “Terremoto is redefining what was as soon as considered…